BioRestorative Therapies Inc (NASDAQ:BRTX) — Market Cap & Net Worth
Market Cap & Net Worth: BioRestorative Therapies Inc (BRTX)
BioRestorative Therapies Inc (NASDAQ:BRTX) has a market capitalization of $2.07 Million ($2.07 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29654 globally and #5786 in its home market, demonstrating a 4.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioRestorative Therapies Inc's stock price $0.23 by its total outstanding shares 8876242 (8.88 Million). Analyse BRTX cash flow conversion to see how efficiently the company converts income to cash.
BioRestorative Therapies Inc Market Cap History: 2015 to 2026
BioRestorative Therapies Inc's market capitalization history from 2015 to 2026. Data shows change from $150.90 Billion to $2.07 Million (-66.19% CAGR).
Index Memberships
BioRestorative Therapies Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2818 of 3165 |
Weight: BioRestorative Therapies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioRestorative Therapies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioRestorative Therapies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
31.65x
BioRestorative Therapies Inc's market cap is 31.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $150.90 Billion | $628.91K | -$7.92 Million | 239930.86x | N/A |
| 2016 | $117.17 Billion | $36.35K | -$8.64 Million | 3222841.27x | N/A |
| 2017 | $131.37 Billion | $81.00K | -$9.44 Million | 1621831.87x | N/A |
| 2018 | $31.95 Billion | $111.00K | -$12.52 Million | 287878.12x | N/A |
| 2019 | $177.52 Million | $130.00K | -$14.65 Million | 1365.58x | N/A |
| 2020 | $244.98 Million | $77.00K | -$11.27 Million | 3181.61x | N/A |
| 2021 | $38.52 Million | $46.00K | -$44.30 Million | 837.45x | N/A |
| 2022 | $24.41 Million | $119.80K | -$13.22 Million | 203.75x | N/A |
| 2023 | $15.44 Million | $145.80K | -$10.42 Million | 105.92x | N/A |
| 2024 | $12.69 Million | $401.00K | -$8.98 Million | 31.65x | N/A |
Competitor Companies of BRTX by Market Capitalization
Companies near BioRestorative Therapies Inc in the global market cap rankings as of May 4, 2026.
Key companies related to BioRestorative Therapies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BioRestorative Therapies Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, BioRestorative Therapies Inc's market cap moved from $150.90 Billion to $ 2.07 Million, with a yearly change of -66.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.07 Million | -80.14% |
| 2025 | $10.43 Million | -17.83% |
| 2024 | $12.69 Million | -17.81% |
| 2023 | $15.44 Million | -36.73% |
| 2022 | $24.41 Million | -36.64% |
| 2021 | $38.52 Million | -84.28% |
| 2020 | $244.98 Million | +38.00% |
| 2019 | $177.52 Million | -99.44% |
| 2018 | $31.95 Billion | -75.68% |
| 2017 | $131.37 Billion | +12.12% |
| 2016 | $117.17 Billion | -22.35% |
| 2015 | $150.90 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BioRestorative Therapies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.07 Million USD |
| MoneyControl | $2.07 Million USD |
| MarketWatch | $2.07 Million USD |
| marketcap.company | $2.07 Million USD |
| Reuters | $2.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more